---
layout: post
title: "Prospective Grant of Exclusive Patent License: Human Therapeutics for Fibrotic Disease"
date: 2026-02-05 18:57:37 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-00022
original_published: 2022-01-06 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of Exclusive Patent License: Human Therapeutics for Fibrotic Disease

**Published:** February 05, 2026 18:57 UTC
**Source:** Federal Register
**Original Published:** January 06, 2022 00:00 UTC
**Document Number:** 2022-00022

## Summary

The National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Inversago Pharma, Inc., located in Montreal, Quebec, Canada, to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/01/06/2022-00022/prospective-grant-of-exclusive-patent-license-human-therapeutics-for-fibrotic-disease)
- API: https://www.federalregister.gov/api/v1/documents/2022-00022

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
